World Investment Advisors LLC Buys Shares of 18,173 Takeda Pharmaceutical Company Limited (NYSE:TAK)

World Investment Advisors LLC purchased a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 18,173 shares of the company’s stock, valued at approximately $258,000.

Several other large investors have also modified their holdings of TAK. Millennium Management LLC lifted its stake in Takeda Pharmaceutical by 87.1% in the 2nd quarter. Millennium Management LLC now owns 4,346,151 shares of the company’s stock valued at $56,239,000 after buying an additional 2,023,707 shares in the last quarter. Cowen AND Company LLC acquired a new position in shares of Takeda Pharmaceutical in the second quarter worth $6,866,000. Van ECK Associates Corp lifted its position in shares of Takeda Pharmaceutical by 21.1% in the second quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock valued at $26,408,000 after acquiring an additional 356,069 shares in the last quarter. FMR LLC boosted its stake in shares of Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after acquiring an additional 286,052 shares during the last quarter. Finally, Stifel Financial Corp increased its position in Takeda Pharmaceutical by 103.9% during the 3rd quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after purchasing an additional 224,594 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Price Performance

NYSE:TAK opened at $13.11 on Thursday. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08. The firm has a market cap of $41.71 billion, a price-to-earnings ratio of 22.60, a price-to-earnings-growth ratio of 0.25 and a beta of 0.51. The company’s 50-day moving average is $13.75 and its two-hundred day moving average is $13.88. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.